Keros Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Keros Therapeutics

02/05/2025 15:28

Keros Therapeutics Inc KROS.OQ KROS.O is expected to show a rise in quarterly revenue when it reports  results on May 6 (estimated) for the period ending March 31 2025

The Lexington Massachusetts-based  company is expected to report a 2,530.5% increase in revenue to $2.183 million from $83 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Keros Therapeutics Inc is for a loss of 24 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Keros Therapeutics Inc is $26.00​, above​ its last closing price of $14.57. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.73
-0.98
-1.14
Missed
-16
Sep. 30 2024
-1.26
-1.28
-1.41
Missed
-10.2
Jun. 30 2024
-1.23
-1.23
-1.25
Missed
-1.5​
Mar. 31 2024
-1.30
-1.35
-1.21
Beat
10.2
​​Dec. 31 2023
-1.35
-1.37
-1.34
Beat
2.5
Sep. 30 2023
-1.34
-1.35
-1.33
Beat
1.3​
Jun. 30 2023
-1.33
-1.34
-1.27
Beat
5.1
Mar. 31 2023
-1.13
-1.12
-1.26
Missed
-12.2

This summary was machine generated May 2 at 14:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)